Thiotepa–melphalan myeloablative therapy for high‐risk neuroblastoma-Reference-Cited by-同舟云学术

Thiotepa–melphalan myeloablative therapy for high‐risk neuroblastoma

Published:2021-03-31 Issue:6 Volume:68 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Yamazaki Fumito¹²^ORCID,Yamasaki Kai³^ORCID,Kiyotani Chikako¹,Hashii Yoshiko⁴,Shioda Yoko¹,Hara Junichi³,Matsumoto Kimikazu¹^ORCID

Affiliation:

1. National Center for Child Health and Development Children's Cancer Center Tokyo Japan

2. Department of Pediatrics Keio University School of Medicine Tokyo Japan

3. Department of Pediatric Hematology and Oncology Osaka City General Hospital Osaka Japan

4. Department of Pediatrics Osaka University Hospital Osaka Japan

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.28896

Reference30 articles.

1. High‐dose chemotherapy and autologous haematopoietic stem cell rescue for children with high‐risk neuroblastoma;Yalçin B;Cochrane Database Syst Rev,2013

2. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma

3. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

4. Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system

5. Treatment of High-Risk Neuroblastoma With Triple-Tandem High-Dose Therapy and Stem-Cell Rescue: Results of the Chicago Pilot II Study

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug delivery assessment of an iron-doped fullerene cage towards thiotepa anticancer drug;Inorganic Chemistry Communications;2022-07

2. The impact of response to induction chemotherapy on the event-free and overall survival in patients with high-risk neuroblastoma: a systematic review and meta-analysis;Pediatric Hematology/Oncology and Immunopathology;2022-06-25

3. To transplant, or not to transplant? That is the question. A patient advocate evaluation of autologous stem cell transplant in neuroblastoma;Pediatric Blood & Cancer;2022-04-04

4. Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies;Cancers;2021-07-13

5. Melphalan/thiotepa;Reactions Weekly;2021-07